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LETTERS
Fatal Case of 
Pneumonia 
Associated with 
Pandemic (H1N1) 
2009 in HIV-
Positive Patient
To the Editor: Pandemic (H1N1) 
2009 virus ﬁ   rst appeared in March 
2009 in Mexico. In June 2009, a pan-
demic was declared by the World 
Health Organization (1). Inﬂ  uenza A 
virus (H1N1) caused a pandemic in 
1918–1919; estimated deaths were 
≈100 million worldwide (2). Symp-
toms of pandemic (H1N1) 2009 are 
similar to those of seasonal inﬂ  uenza 
(fever, cough, sore throat, body aches, 
headache, chills, and fatigue) (3). Pan-
demic (H1N1) 2009 should be con-
sidered in the differential diagnosis 
of patients with acute febrile respira-
tory illness who have been in contact 
with persons with conﬁ  rmed inﬂ  uenza 
or reside in areas where inﬂ  uenza has 
been reported (2).
Although most cases of pandem-
ic (H1N1) 2009 in the United States 
have been mild, 2%–5% of infected 
persons have required hospitalization 
(2). Immunosuppressed persons, the 
elderly, persons with underlying lung 
or cardiac disease, pregnant women, 
persons with diabetes, obese persons, 
and children <5 years of age are at in-
creased risk for this disease (4).
We report pneumonia associated 
with pandemic (H1N1) 2009, which 
resulted in respiratory and renal fail-
ure and death, in a 39-year-old HIV-
positive woman. She had type 1 dia-
betes and a diagnosis of AIDS 7 years 
ago and had received highly active 
antiretroviral therapy. She also had an 
ill child at home with an inﬂ  uenza-like 
illness.
Her medical history included 
pleuropericardial Nocardia spp. infec-
tion, recurrent pleural effusions requir-
ing thoracentesis, and hepatomegaly 
of unknown cause. Her most recent 
CD4 cell count was 166 cells/μL 
with undetectable viral load 1 month 
before admission. Medications pre-
scribed included combivir, efavirenz, 
and trimethoprim/sulfamethoxazole 
but she was noncompliant. She had re-
ceived the 2008–09 seasonal inﬂ  uenza 
vaccine and pneumococcal vaccine.
The patient was admitted to 
Winthrop-University Hospital (Mi-
neola, NY, USA) on June 5, 2009, 
for community-acquired pneumonia. 
She received empiric moxiﬂ  oxacin 
and atovaquone. Because of concern 
for persistent Nocardia spp. infection, 
she was also treated with doxycycline. 
The result of a rapid inﬂ  uenza  test 
(QuickVue; Quidel, San Diego, CA, 
USA) was negative for a nasal swab 
specimen on day 1 of hospitalization. 
Over the next 48 hours, her clinical 
status deteriorated, and she experi-
enced worsening hypotension and re-
spiratory distress.
On admission, she had fever 
(101°F) for 3 days, pulse rate of 109 
beats/min, blood pressure of 86/52 mm 
Hg, respiratory rate of 22 breaths/min 
(oxygen saturation of 88% on room 
air), generalized weakness, nonpro-
ductive cough, and increasing short-
ness of breath. She was alert and ori-
ented. Physical examination showed 
decreased breath sounds at bases, 
hepatomegaly, and bilateral edema in 
the lower extremities. Laboratory tests 
showed 3,000 leukocytes/mm3 (93% 
neutrophils, 2% bands, and 3% lym-
phocytes), hemoglobin level of 12.7 g/
dL, and 118,000 platelets/mm3. Other 
laboratory values were blood urea ni-
trogen 66 mg/dL, creatinine 2.9 mg/dL, 
creatinine phosphokinase 2,276 IU/L, 
and lactic acid 3.6 mmol/L (anion gap 
13). A chest radiograph showed mod-
erate pleural effusion in the right lung 
and retrocardiac air space disease. Test 
results for inﬂ  uenza virus, respiratory 
ﬂ  uorescent antibodies (D3 Ultra DFA 
Respiratory Virus Screening and In-
fectious Disease Kit; Diagnostic Hy-
brids, Inc., Athens, OH, USA), and 
virus culture were negative.
The patient was transferred to the 
intensive care unit and required intu-
bation, pressor support, and continu-
ous venovenous hemoﬁ  ltration for ﬂ  u-
id removal. Empiric oseltamivir (150 
mg 2×/d) was started on hospital day 
3; moxiﬂ  oxicin was discontinued, and 
meropenem was given for pneumonia 
(5). Thoracentesis showed transuda-
tive ﬂ  uid negative for acid-fast bacilli, 
bacteria, and fungi.
Results of blood cultures and 
urine analysis for Legionella spp. 
antigen were negative. Repeat chest 
radiography showed a right-sided 
pneumothorax and worsening bilat-
eral airspace disease. A chest tube was 
inserted in the right lung, and bron-
choscopy was performed on hospi-
tal day 5. Results of bronchoalveolar 
lavage were negative for Pneumocys-
tis jiroveci, virus inclusions, fungi, ac-
id-fast bacilli, bacteria, and mycobac-
teria. However, clusters of ﬁ  lamentous 
organisms were seen. On hospital day 
5, results of a second rapid inﬂ  uenza 
test, respiratory ﬂ  uorescent antibody 
test, and nasopharyngeal virus culture 
were negative. Diagnosis was based 
on a positive result for pandemic 
(H1N1) 2009 by real-time reverse 
transcription–PCR (RT-PCR) for a 
nasopharyngeal swab specimen (New 
York State Department of Health). De-
spite empiric treatment with oseltami-
vir, the patient died on June 15, 2009 
(day 11 of hospitalization).
Symptoms of pandemic (H1N1) 
2009 in HIV-infected persons are not 
known. However, these persons have 
a higher risk for complications. In pre-
vious seasonal inﬂ  uenza  outbreaks, 
HIV-infected persons had more severe 
infections and increased hospitaliza-
tion and mortality rates (6).
Although a diagnosis of pandemic 
(H1N1) 2009 was ﬁ  rst considered for 
our patient because of her ill child, she 
was not initially treated with oseltami-
vir because of the negative inﬂ  uenza 
test result and concern for opportu-
nistic infections. Only the result of an 
RT-PCR for pandemic (H1N1) 2009 
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was positive. No other pathogens were 
detected in her blood, urine, sputum, 
bronchoalveolar lavage, or thoracen-
thesis ﬂ  uid.
Empiric treatment in patients with 
pandemic (H1N1) 2009 should be con-
sidered in those seeking treatment for 
inﬂ  uenza-like symptoms, especially in 
the setting of sick contacts with respi-
ratory illnesses. Rapid inﬂ  uenza tests, 
respiratory ﬂ  uorescent antibody tests, 
and viral cultures may not provide a 
diagnosis. An RT-PCR for pandemic 
(H1N1) 2009 may be needed to pro-
vide a diagnosis.
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Human Herpesvirus 
8 in Healthy Blood 
Donors, Argentina
To the Editor: Human herpesvi-
rus 8 (HHV-8), or Kaposi sarcoma–
associated herpesvirus, is associated 
with malignant disorders such as 
Kaposi sarcoma, primary effusion 
lymphoma, and multicentric Castle-
man disease. Although HHV-8 does 
not necessarily cause life-threatening 
infection in healthy persons, it causes 
more severe infection in those who 
are immunocompromised, such as 
organ recipients and HIV-infected 
persons.
HHV-8 has been found in a num-
ber of clinical specimens (blood, sa-
liva, and semen) from persons with 
HHV-8 related diseases (1,2). Identi-
ﬁ  cation of infectious virus in lympho-
cytes from a healthy blood donor and 
evidence that HHV-8 might be trans-
mitted by blood has raised concern 
about the safety of the blood supply 
(3,4). Few studies have detected vi-
ral DNA in blood samples of blood 
donors from areas with low HHV-8 
prevalence (5–7). During January 
2000 and December 2002, the Virol-
ogy Department, National Institute of 
Infectious Diseases, Administración 
Nacional de Laboratorios e Insti-
tutos de Salud, “Dr C G. Malbrán” 
conducted an HHV-8 serosurvey of 6 
blood banks from 5 South American 
regions and found overall seropreva-
lence to be 3.7% (range 1.9%–6.7%). 
The 6.7% seroprevalence from a 
blood bank in Buenos Aires city was 
substantially higher than that of other 
blood banks (8).
From July 2004 through January 
2005, to look for the virus in blood 
and saliva, we conducted the study 
reported here, an HHV-8 survey at 
the same blood bank. A total of 577 
volunteer blood donors (431 men 
and 146 women), mean age 39 years 
(range 17–76 years), were enrolled 
at the Hemotherapy Service, Hospi-
tal of Infectious Diseases “Francisco 
Javier Muñiz.” The protocol was ap-
proved by the Teaching and Research 
Committee. 
Serum and whole blood were col-
lected from all 577 donors, and paired 
blood–saliva samples were obtained 
from 394. Serum samples were rou-
tinely tested for hepatitis B and C 
viruses, HIV, human T-lymphotropic 
viruses I and II, Treponema pallidum, 
Brucella spp., and Trypanosoma cru-
zi; results were used to determine as-
sociations between HHV-8 and these 
agents. Specimens were stored at 
–20°C until serologic and molecular 
investigation at the Virology Depart-
ment, National Institute of Infectious 
Diseases. 
Serologic screening for HHV-8 
infection was performed by indirect 
immunoﬂ   uorescence assay by using 
lytically induced cells; serum samples 
were diluted 1:40 (8). Then 45 blood 
and 39 paired blood–saliva samples 
from HHV-8-seroreactive donors were 
investigated for viral genome by open 
reading frame 26 nested PCR. DNA 
was puriﬁ  ed from 0.3 mL of whole 
blood by using FlexiGene DNA Kit 
(QIAGEN, Gmbh, Hilden, Germa-
ny); concentrations and quality were 
measured with a UV spectrophotom-
eter, and 1 μg was used for PCR. The 
QIAamp DNA Mini Kit (QIAGEN, 
Gmbh,) was used to obtain DNA from 
0.2-mL saliva samples. Crude pel-
lets were resuspended in 20μL of Tris 
EDTA, pH 8, then 5 μL were added 
to the PCR. Quality of DNA isolated 
from negative PCR samples was test-
ed by amplifying the human house-
keeping gene β-globin. In addition, 
inhibitors were investigated by add-
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